A founder with four collapsed ventures behind him rarely walks into Sequoia Capital and walks out with a term sheet. Harsimarbir Singh pulled it off anyway, not because his track record sparkled, but because the problem he chose next dwarfed everything he had touched before.
That puzzle sits at the center of nearly every Indian household: elective surgery devouring time, trust, and money inside a fog of opaque bills, unverified credentials, and labyrinthine hospital paperwork. In August 2018, Singh joined forces with Dr. Vaibhav Kapoor and Dr. Garima Sawhney to dismantle that chaos. The result became Pristyn Care, a healthtech unicorn that now inches toward a public debut while wrestling with a fundamental tension: strong revenue paired with a loss figure that refuses to budge at matching speed.
The model sounds straightforward. Transparent pricing, American FDA sanctioned equipment, and a personal coordinator assigned to every case. That proposition has multiplied into a network spanning dozens of cities, approximately 800 partner surgical centers, and over 400 in-house surgeons performing procedures across more than 50 medical conditions.
Underneath the expansion sits an important strategic turn. For years, the company functioned as an asset-light operator, deploying its own surgeons and technology into rented operating theaters inside existing hospitals. That kept capital demands minimal and fueled rapid geographic growth. Now management is moving in the opposite direction, buying and running its own facilities. A South Delhi hospital reportedly hit double-digit margins within weeks of opening while still operating below full capacity.
The shift makes intuitive sense. Own the infrastructure completely, capture the entire patient experience, and stop sharing margins with partner hospitals on every surgery. The risks are equally clear. Real estate, equipment, and staffing costs now land directly on the balance sheet, disciplines the company never had to manage before.
Financial data from FY24 reveal the stakes. Consolidated revenue climbed 28 percent year-on-year to roughly Rs 632 crore. The core surgery business slashed its EBITDA burn by 42 percent. Yet the net loss hovered stubbornly near Rs 381 crore, almost unchanged from the previous year. A particularly sobering metric: approximately Rs 1.69 spent to earn each single rupee of revenue, underscoring how painfully expensive digital patient acquisition remains.
Valuation mirrors this mixed picture. Unicorn status arrived in December 2020 at roughly $1.2 billion. The Series E round a year later pushed that figure toward $1.4 billion. According to Tracxn data from November 2025, the valuation has since settled back to approximately $1.17 billion, about Rs 10,300 crore, reflecting the broader repricing of Indian consumer-tech firms since 2022. Total capital raised exceeds $180 million across seven rounds, with Peak XV Partners, Tiger Global Management, and Hummingbird Ventures among the lead backers.
The founders still hold 48.08 percent of the company, a collective stake worth nearly Rs 4,970 crore. The public listing deadline has slipped once already: from an FY27 target anchored to FY25 profitability to a revised FY28 timeline now tied to FY26 profitability. Reaching that milestone likely depends on shrinking the net loss, proving the hospital-ownership model can replicate its early margins across multiple locations, and bringing acquisition costs down far enough that growth starts looking efficient rather than merely expensive. Until those pieces lock into place, the IPO remains a publicly declared aspiration, not a scheduled event.
